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Abstract
While modulation of regulatory T cell (Treg) function and adoptive Treg transfer are being explored as therapeutic
modalities in the context of autoimmune diseases, transplantation and cancer, their role in HIV-1 pathogenesis remains less
well defined. Controversy persists regarding their beneficial or detrimental effects in HIV-1 disease, which warrants further
detailed exploration. Our objectives were to investigate if functional CD4+ Tregs can be isolated and expanded from HIV-1-
infected individuals for experimental or potential future therapeutic use and to determine phenotype and suppressive
capacity of expanded Tregs from HIV-1 positive blood and tissue. Tregs and conventional T cell controls were isolated from
blood and gut-associated lymphoid tissue of individuals with HIV-1 infection and healthy donors using flow-based cell-
sorting. The phenotype of expanded Tregs was assessed by flow-cytometry and quantitative PCR. T-cell receptor ß-chain
(TCR-b) repertoire diversity was investigated by deep sequencing. Flow-based T-cell proliferation and chromium release
cytotoxicity assays were used to determine Treg suppressive function. Tregs from HIV-1 positive individuals, including
infants, were successfully expanded from PBMC and GALT. Expanded Tregs expressed high levels of FOXP3, CTLA4, CD39
and HELIOS and exhibited a highly demethylated TSDR (Treg-specific demethylated region), characteristic of Treg lineage.
The TCRß repertoire was maintained following Treg expansion and expanded Tregs remained highly suppressive in vitro.
Our data demonstrate that Tregs can be expanded from blood and tissue compartments of HIV-1+ donors with preservation
of Treg phenotype, function and TCR repertoire. These results are highly relevant for the investigation of potential future
therapeutic use, as currently investigated for other disease states and hold great promise for detailed studies on the role of
Tregs in HIV-1 infection.
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Introduction
CD4+ regulatory T cells (Tregs) have been shown to be essential
for the development and the maintenance of peripheral tolerance
and immune homeostasis [1]. Indeed, Treg dysfunction is
associated with allergy, autoimmunity, cancer or early graft
rejection [2]. In the context of infectious diseases, Tregs have
the potential to limit excessive inflammatory immune responses,
thereby reducing tissue damage, but can also suppress antimicro-
bial immune responses and promote pathogen persistence [3].
The role of Tregs during HIV-1 infection remains controversial
[4,5,6]. During the course of HIV-1 disease progression, microbial
translocation from the gut, viral factors and co-infections such as
human cytomegalovirus (hCMV) have emerged as the major
causes of persistent immune activation and have been associated
with mortality and non-AIDS morbidity [7]. In this context, Treg
activity could have a beneficial effect through suppression of
generalized chronic immune activation, but also through inhibi-
tion of activated CD4+ T cells and subsequent control of viral
replication, as demonstrated by Moreno-Fernandez et al. [8]. In
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contrast, Tregs may play a detrimental role through inhibition of
anti-HIV-1 immune responses [9,10,11,12], thus promoting HIV-
1 persistence at the host’s expense. HIV-1 infection appears to
directly and indirectly modulate Tregs in vivo, as suggested by data
demonstrating that individuals with chronic HIV-1 infection have
higher Treg frequencies than individuals who control HIV-1
infection and healthy control subjects [13,14]. This observation
has not been fully elucidated to date, but could be explained by
preferential survival, tissue redistribution, increased proliferation,
or conversion of non-regulatory T cells into Tregs in chronic HIV-
1 infection [4,15].
One of the main challenges for detailed functional analyses of
Tregs in HIV-1 disease and their potential for future clinical
application is the paucity of the natural Treg population in human
peripheral blood, where thymus-derived Treg represent roughly
1–10% of the mature CD4+ T cell pool [16]. This poses an even
greater challenge in progressive HIV-1 infection, where chronic
viral replication and immune activation contribute to profound
CD4+ T cell loss [17]. The functional characterization of Tregs in
individuals with advanced HIV-1 disease, HIV-1-infected infants,
for which only very small volume samples can be obtained, or
from lymphoid or mucosal tissue sites where sample size is often
limited, is therefore difficult. Based on our previous data
demonstrating that ex vivo suppressive function of freshly isolated
Tregs was preserved in HIV-1 positive individuals [13], we
hypothesized that functional Tregs can be expanded in vitro from
HIV-1-infected blood and tissue with preservation of phenotype
and suppressive capacity.
We here describe the successful isolation and in vitro expansion
of functional CD4+ Tregs from HIV-1-infected individuals,
including HIV-1 controllers, individuals with progressive untreat-
ed HIV-1 infection, small volume specimen from HIV-1-infected
infants and biopsies of gut-associated lymphoid tissue (GALT).
Expanded Tregs were highly suppressive and exhibited an
activated Treg phenotype with high expression of Treg markers
and a demethylated TSDR, suggesting functional Treg lineage as
opposed to activation-induced FOXP3 expression. We believe that
our findings are of high relevance for potential future therapeutic
exploration of Tregs and in addition will allow for more detailed
investigations into the role and function of Tregs in HIV-1 disease.
Methods
Study subjects
The study was approved by the Institutional Review Board of
the Massachusetts General Hospital (MGH, Boston, MA) and was
conducted in accordance with the MGH human experimentation
Table 1. Summary of clinical data of the HIV-1-infected study subjects.
Patient type PBMC/Gut Sample HAART Treated Age (years) Gender
Plasma viral load
(HIV RNA copies/ml) CD4 count, (cells/ml)
Treated Ileum Yes 45 Female ,50 153
Controller Duodenum, Colon No 61 Male ,20 690
Controller Colon No 60 Male ,20 998
Controller PBMC No 50 Female ,50 425
Controller PBMC No 51 Female ,50 460
Controller PBMC No 59 Female ,50 1283
Controller PBMC No 56 Female ,50 1786
Controller PBMC No 62 Male ,50 618
Controller PBMC No 53 Male ,50 734
Controller PBMC No 62 Male ,50 825
Controller PBMC No 43 Male ,50 1018
Controller PBMC No 44 Male 164 1018
Controller PBMC No 61 Male 243 548
Viremic PBMC No 48 Male 2,274 533
Viremic PBMC No 57 Female 4,090 297
Viremic PBMC No 48 Male 4,100 271
Viremic PBMC No 42 Male 7,960 362
Viremic PBMC No 26 Male 11,349 699
Viremic PBMC No 39 Male 21,500 1047
Viremic PBMC No 51 Male 27,000 475
Viremic PBMC No 40 Male 41,800 898
Viremic PBMC No 49 Male 44,500 2
Viremic PBMC No 46 Male 45,700 756
Viremic PBMC No 49 Male 68,460 295
Viremic PBMC No 29 Male 169,000 369
Viremic PBMC No 34 Male 204,000 312
Viremic PBMC No 1 Male 1,977,540 757
doi:10.1371/journal.pone.0086920.t001
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guidelines. Written informed consent was obtained for all study
participants.
Blood samples were drawn from 10 HIV-1 controllers with
asymptomatic HIV-1 infection who maintained a plasma viremia
below 300 copies/ml (median CD4 count: 779 cells/ml, inter-
quartile range (IQR): 526–1,084) in the absence of antiretroviral
therapy, 13 individuals with chronic untreated HIV-1 infection
(median viral load: 41,800 RNA copies/ml, IQR: 6,030–118,730
and median CD4 count: 362 cells/ml, IQR: 283–616) (Table 1)
and a vertically HIV-1-infected infant (age: 511 days, viral load:
1,977,540 RNA copies/ml, CD4 count: 757). Blood samples from
5 HIV-1 uninfected individuals were studied as control specimen.
Gut biopsies from 1 HIV-1-negative and 3 HIV-1-infected
individuals (1 on antiretroviral therapy, 2 elite controllers) were
also used in this study.
Isolation of T cell subsets from peripheral blood and
GALT
CD4+ T Cell-enriched PBMC were isolated from peripheral
blood by density centrifugation using the RosetteSep enrichment
kit (Ficoll-Histopaque; Sigma-Aldrich and STEMCELL Tech-
nologies) and labeled with anti-CD3-PE-Cy7 (BD Pharmingen),
CD4-FITC (eBioscience), CD25-APC (eBioscience), CD127-PE
(BD Pharmingen).
Cryopreserved PBMC samples were stained using the same
panel as described above except for the addition of an exclusion
channel to select for viable cells (Invitrogen).
Pinch biopsies from HIV-positive individuals were obtained by
endoscopy and an Ileum biopsy from an HIV-negative individual
was obtained from a laparoscopic small bowel resection. All gut
samples were provided by the Ragon Institute tissue platform.
After collection, biopsies underwent two rounds of collagenase
type II (Sigma-Aldrich) digestions followed by filtration [18] and
were stained with the same panel as the fresh PBMC described
above.
CD3+CD4+CD25+CD127low Treg and CD3+CD4+CD252
CD127+ Tconv controls subsets were sorted on a FACS Aria cell
sorter (BD Biosciences) equipped for handling biohazardous
material.
Expansion of CD4+ Tregs and conventional T cells (Tconv)
Tregs and Tconvs were activated with anti-CD3/anti-CD28-
coated microbeads (Invitrogen) at a 1:1 bead-to-cell-ratio. On day
2, media volume was doubled and exogenous IL-2 was added
(300 U/ml, NIH Aids Research & Reference Reagent Program)
Figure 1. Cell sorting, FOXP3 TSDR and gene expression. A. Flow-cytometry gating strategy used to isolate CD25+CD127low regulatory T cells
(Tregs) and CD252CD127+ conventional T cells (Tconv) from CD4+ T cells (Left Panel). Expansion fold change of Tregs isolated from HIV-1-infected
(dark grey) (n = 8 controllers + 13 chronic untreated) and healthy (light grey) (n = 4) individuals during 7 days of cell culture (right Panel). B. Relative
mRNA expression in arbitrary units (A.U.) of FOXP3 and IL-10 quantified by real time PCR in expanded Tregs (n = 3 controllers+2 chronic untreated)
and Tconvs (n = 2 controllers+2 chronic untreated) isolated from HIV-1 infected individuals after 7 days of culture. C. Frequency of demethylation of
the Treg Specific Demethylation (TSDR) region of the FOXP3 gene in expanded Tregs and Tconvs after 7 days of culture as assayed by real time PCR.
Empty symbols represent HIV-1 controllers and solid symbols HIV-1 chronic untreated individuals.
doi:10.1371/journal.pone.0086920.g001
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Figure 2. Phenotyping of expanded Tregs by flow cytometry. A. Representative examples of gating strategy used for CD25+FOXP3+ staining
by flow-cytometry of ex vivo PBMC (upper panel) isolated from a HIV-1 controller and matched expanded Tregs (lower panel) at day 7 of expansion. B.
Expression of different Tregs markers quantified by flow-cytometry of expanded (day 7) and ex vivo unexpanded Tregs and Tconvs. MFI =Mean
Fluorescence intensity. Empty symbols represent HIV-1 controllers and solid symbols HIV-1 chronic untreated individuals. C. Representative example
of flow-cytometry gating strategy used to phenotype Tregs, Tconvs (n = 3 controllers+9 chronic untreated) and ex vivo CD4 T cells (n = 3 controllers+3
chronic untreated) isolated from HIV-1 positive individuals based on their CD45RA and FOXP3 expression profiles [41]. The left dot plot shows ex vivo
Tregs Expanded from HIV-1+ Donors Are Functional
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[19]. On day 5, cells were counted and fresh media added. On day
7 expanded T cells were assayed for their suppressive function and
the remaining cells were cryopreserved for further analysis.
Immunophenotyping of T cell subsets by flow-cytometry
Cryopreserved expanded Tregs and Tconvs were thawed and
immunostained with anti-CD3-PE-Cy7, anti-CD4-qdot655 (Invi-
trogen), anti-CD25-PE-Cy5 (eBiosciences), anti-CD39-FITC
(eBioscience), anti-CD45RA-horizon v450 (BD Pharmingen),
anti-FOXP3-PE (clone PCH101, eBiosciences), anti-CTLA4-
APC (BD Pharmingen), anti-HELIOS-FITC (Biolegend). For
intracellular staining, the eBioscience FOXP3 staining buffer kit
was used. Dead cells were eliminated using the LIVE/DEADH
Fixable Blue Dead Cell Stain Kit (Invitrogen). Flow-cytometry
data were acquired on a LSR Fortessa (BD Biosciences).
RNA isolation and real-time RT-PCR
RNA was isolated using the RNeasy Plus Kit (Qiagen) and
retro-transcribed using the SuperScript III Reverse Transcriptase
(Invitrogen). Primers for FOXP3 (forward (f): 59-CAGCACA-
TTCCCAGAGTTCCTC-39 and reverse (r): 59- GCGTG-
TGAACCAGTGGTAGATC-39) and IL10 (f: 59-GCGCTG-
TCATCGATTTCTTC-39 and r: 59-ATAGAGTCGCCACC-
CTGATG-39) were designed using Primer3 [20] and chosen to
span an exon-exon junction. Real-time PCR was performed in a
Roche Applied Science LightCycler 480 using the SYBR Green I
Master kit (Roche). RNA polymerase II (f: 59-GCATG-
TTCTTTGGTTCAGCA-39 and r: 59-GGTCATTCCACTCC-
CAACAC-39) gene expression was used to normalize the data by
the Pfaffl method [21].
Epigenetic analysis and TCR sequencing
Genomic DNA was isolated from Tregs and Tconvs using the
DNeasy Blood & Tissue Kit (Qiagen). Quantification of TSDR
demethylation by real-time PCR was performed by Epiontis
(Berlin, Germany) as previously described [22].
The TCR diversity of ex vivo unexpanded and in vitro expanded
Tregs was analyzed using a next generation sequencing protocol
(NGS) [23,24]. Briefly, RNA was isolated using the RNeasy plus
kit (Qiagen) and cDNA was synthesized with SuperScript III
Reverse Transcriptase and oligo-dT primers (Invitrogen) [25].
Linear amplification of the cDNA was performed on a T3000
thermocycler (Biometra). The amplified samples were analyzed by
NGS on the Genome Sequencer FLX (Roche) using the titanium
platform. After TCR sequencing, the Vß-, Jß variants and the
CDR3 were identified.
Assessment of Treg suppressive function using CFSE
proliferation assays
Cryopreserved PBMC were labeled with CFSE (Invitrogen) and
cultured in the presence or absence of fresh autologous CD4+
Tregs or Tconvs at day 7 of expansion with anti-CD2/anti-CD3/
anti-CD28 microbeads (Miltenyi Biotec) at a 1:1 bead-to-cell-ratio.
After 4 days of co-culture, cells were stained with anti-CD3-
PECy7, anti-CD4-APC (BD Pharmingen) and anti-CD8-AF700
(BD Pharmingen).
51Chromium release assay
Epstein-Barr virus (EBV) immortalized B-cell lines (BCL) were
established and cytotoxicity assays were performed as previously
described [26,27]. Briefly, BCL loaded with a peptide specific for
the HLAB*5701-restricted HIV-Gag-epitope KF11 (KAFSPE-
VIPMF) were used as target cells. Targets were incubated with
KF11-specific cytotoxic T cell clones at a 1:1 ratio (Target:Effec-
tor) with or without expanded Tregs at a 1:1 ratio (Treg:Effector).
Statistical analysis
All statistical analyses were performed using Prism 5.0a
(GraphPad Software). Non-parametric tests of significance were
performed throughout all analyses, using Kruskal-Wallis and
Mann-Whitney testing for intergroup comparisons. P values of less
than 0.05 were considered significant (*:P,0.05; **: P,0.01;
***:P,0.001; ****:P,0.0001).
Results
Successful expansion of Tregs isolated from HIV-1
positive and negative blood donors
The combination of high expression CD25 and low expression
of CD127 has been described as a reliable phenotype to identify
and isolate CD4+ Tregs [28]. Furthermore, Tregs constitutively
express FOXP3, a key regulator of their development and function
[29,30], and we and others described a strong inverse correlation
between CD127 and FOXP3 expression on CD4+CD25hi T cells,
including in HIV-1 positive individuals [13,14,28,31]. Peripheral
CD4+CD25+CD127low Tregs and CD4+CD25-CD127+ conven-
tional T cells (Tconvs) controls were isolated from the peripheral
blood of individuals with chronic untreated HIV-1 infection, HIV-
1-infected individuals with spontaneous control of HIV-1 infection
(HIV controllers) and non-infected healthy donors (gating scheme
Figure 1A, left). Tconvs controls underwent identical culture
conditions for comparison. Isolated Tregs and Tconvs were
stimulated and cultured in the presence of IL-2 for 7 days [19].
Our data show that ex vivo sorted Tregs from HIV-1 positive
donors were successfully expanded (Figure 1A, right), with a
median fold change of 49 (interquartile range (IQR): 26.4–67.7) at
day 7. Treg cultures could be extended at least 19 days (data not
shown), demonstrating that Tregs could be successfully expanded
beyond the 7 days studied here. No significant expansion
differences between individuals with spontaneously controlled,
chronic untreated HIV-1 infected and healthy control subjects
were observed.
Expanded CD4+CD25+CD127low T cells exhibit an
activated Treg phenotype
After successful expansion of Tregs from HIV-1-infected and
uninfected individuals, we next investigated and quantified the
expression of selected Treg markers. Real-time PCR showed that
expanded Tregs expressed high levels of FOXP3 and the
suppressive cytokine IL-10 [32] compared to Tconvs expanded
as controls under the same conditions (Figure 1B). In humans
FOXP3 does not represent an exclusive Treg marker and can
transiently be expressed by activated conventional T cells [33] to
negatively regulate their proliferation and cytokine production,
therefore limiting their activation state [34]. Epigenetic analysis of
CD4+ T cells from PBMC, the middle dot plot represents an example of expanded Tregs (black dots) and Tconvs (light grey dots). The right histogram
graph quantifies the different Treg subsets in HIV-1 positive individuals. Gate 1 and white columns represent ‘‘resting’’ CD45RA+FOXP3low Tregs, gate
2 and grey columns represent ‘‘non-suppressive cytokine-secreting’’ CD45RA2FOXP3low T cells and gate 3 and black columns represent ‘‘activated’’
CD45RA2FOXP3high Tregs.
doi:10.1371/journal.pone.0086920.g002
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the FOXP3 TSDR (Treg-specific demethylated region) using a
real-time PCR assay has recently been described as a reliable
method to quantify and distinguish regulatory T cells from
conventional activated T cells [22]. The DNA of this region is
found to be methylated in activated and resting non-regulatory T
cells, while the FOXP3 TSDR of T cells from the regulatory
Figure 3. The TCR repertoire is not altered after in vitro expansion of Tregs. A. Degree of expansion of the TCRß repertoire (i.e. number of
TCRs in a sample that belongs to an individual clone and expressed as percentage of total reads) from 26104 ex vivo sorted unexpanded (light grey)
and 26104 in vitro expanded (Day 14; dark grey) Tregs isolated from the same original PBMC specimen. B. Distribution of variable-gene (Vß-gene)
variants from 26104 ex vivo sorted unexpanded (light grey) and 26104 in vitro expanded (Day 14; dark grey) Treg TCR-b clones isolated from the
same PBMC specimen. C. Distribution of joining-gene (Jß-gene) variants from 26104 ex vivo sorted unexpanded (light grey) and 26104 in vitro
expanded (Day 14; dark grey) Treg TCR-b clones isolated from the same PBMC specimen.
doi:10.1371/journal.pone.0086920.g003
Tregs Expanded from HIV-1+ Donors Are Functional
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lineage is constitutively demethylated in this region [35]. In our
study the FOXP3 TSDR of expanded Tregs was highly
demethylated, while it was found to be methylated in expanded
Tconvs (Figure 1B, left). Expanded Tregs therefore revealed high
expression levels of stable FOXP3, suggesting their origin derived
from true functional regulatory T cell lineage.
We next sought to carefully characterize the phenotype of
expanded Tregs by comparing ex vivo unexpanded and expanded
Tregs and Tconvs using flow cytometry. Examples of CD25/
FOXP3 coexpression in expanded and ex vivo unexpanded Tregs
from HIV controllers are shown in Figure 2A. While mean
fluorescence intensity of CD25 expression did not differ between
expanded Tregs and Tconvs (data not shown), as expected we
found significantly higher FOXP3 expression in Tregs (Figure 2B).
CTLA4 can transmit inhibitory signals to antigen presenting cells
and is important for Treg function [36,37]. The ectoenzyme
CD39 was also shown to participate in the suppressive function of
Tregs [38] and in HIV-1 infection, CD39 expression on Tregs was
recently shown to correlate with disease progression [14]. Similarly
to FOXP3, our data show higher CTLA4 and CD39 expression in
expanded Tregs compared to conventional T cells (Figure 2B),
suggesting that relative differences of CTLA4, CD39 and FOXP3
expression levels between Tconvs and Tregs were maintained after
expansion. The Treg marker HELIOS has recently been
suggested as a more specific marker of thymic-derived Tregs
[39] and in our study, the frequency of cells expressing this
molecule was high in both ex vivo unexpanded and in vitro expanded
Tregs (median 72.5%, IQR: 70.1–80.6%, and median 64.8%
IQR: 55.2–77.8%, respectively). HELIOS was not expressed in
expanded Tconvs (Figure 2B) and the decrease of HELIOS
expression found after stimulation in our culture is in line with the
decreased of HELIOS-expressing FOXP3+ Tregs described after
in vitro stimulation in a previous study, suggesting that obtaining
large numbers of FOXP3+HELIOS+ Tregs after several rounds of
stimulation may require use of a stabilizing reagent [40].
In 2009, Miyara et al. proposed an elegant classification scheme
for the functional delineation of human CD4+ T cells based on the
expression of FOXP3 and CD45RA [41]. Using this classification
and based on ex vivo CD4+ T cell comparison as a reference,
expanded Tregs showed a high amount of CD45RA2FOXP3high
activated Tregs, while expanded Tconvs were mostly constituted
of CD45RA2FOXP3low cytokine-secreting non-suppressive T
cells (Figure 2C).
In summary, the high expression of FOXP3 bearing a
demethylated TSDR, high CTLA4, CD39 and HELIOS as well
as the CD45RA2FOXP3high phenotype suggest that after 7 days
of expansion the CD4+CD25+CD127low T cells represent Tregs of
an activated phenotype.
Treg expansion did not significantly alter the TCR
repertoire
After determination of the phenotype of expanded Tregs, we
next investigated if in vitro expansion would alter T cell receptor
diversity and selectively expand specific Treg clones. The next
generation sequencing analysis of the Vß-CDR3-Jß region
allows for identification of unique T cell clones [23]. We
sequenced the Vß, Jß variants and the CDR3 regions of the
TCR of ex vivo unexpanded and in vitro expanded Tregs in a subset
of HIV-1-infected individuals. No specific individual clones were
preferentially expanded in our study sample (Figure 3A) and the
TCR-b V-(Figure 3B) and J-usage (Figure 3C) did not appear to
significantly differ after expansion, suggesting that the use of anti-
CD3/anti-CD28-coated beads did not significantly alter the
breadth of the TCR-b repertoire. These results support work by
Hoffmann et al. who found that the TCR Vb-chain of Tregs in
vitro stimulated with artificial antigen-presenting cells proliferated
polyclonally and did not lose clonotypes [42].
Expanded Tregs from HIV-1-infected individuals potently
suppress T cell proliferation and HIV-1-specific
cytotoxicity
Tregs are ultimately defined through their suppressive capacity.
We therefore next explored if expanded Tregs isolated from HIV-
1-infected individuals remained suppressive after expansion using
standardized flow-based proliferation assays [13], where CFSE-
labeled activated responder cells were cultured in the presence or
absence of expanded Tregs (or Tconv controls). Our data
demonstrate that expanded Tregs isolated from HIV-1-positive
individuals have preserved potent suppressive capacity. In
contrast, no significant suppression of proliferation was observed
in the presence of expanded conventional T cells (Figure 4A,B).
Expanded CD4+ Tregs isolated from HIV-1-positive and negative
individuals did not show significantly different suppressive
capacities (Figure 4A,B). Expanded Tregs isolated from controllers
and chronic untreated HIV-1 infected individuals were also equal
in their ability to suppress T cell proliferation in this experimental
system (data not shown), in line with preserved ex vivo Treg
function in these two patient populations, as previously described
[13]. Moreover when compared to our previous study [13], the
suppressive function of expanded Tregs and ex vivo unexpanded
Tregs isolated from HIV-1 positive individuals were not signifi-
cantly different.
Using expanded Tregs isolated from HIV-1 positive donors, we
next tested their capacity to suppress the cytolytic function of HIV-
1-specific cytotoxic T lymphocyte (CTL) clones in a 51chromium
release assay. Figure 4C shows a representative example of potent
suppression by expanded Tregs of the cytotoxic activity of an
Figure 4. Suppressive function of expanded Tregs. A. Suppressive activity of expanded Tregs from HIV-1+ (n = 7 controllers +11 chronic
untreated individuals) and healthy controls (n = 4) on activated CD8+ T cells (left) and CD4+ T cells (right). Columns represent activated T cells (white)
co-cultured with autologous expanded Tregs (black) or Tconvs (grey). A suppressive activity of 100% indicates that the proliferation of activated T
cells was completely inhibited and a negative suppressive activity signifies that the proliferation of T cells was higher than in the condition ‘‘T cells
alone’’. B. Representative example of a flow-based Treg suppressive assay after 4 days of co-culture. CFSE dilution of activated CD8+ T cells (upper
panel) and CD4+ T cells (lower panel) are represented as histograms. Left columns show CFSE dilution of bead-activated T cells from frozen PBMC, the
other columns represent activated T cells co-cultured with autologous expanded Tregs (middle) or Tconvs (right). C. 51Chromium release assay.
Representation of the cytotoxic function (% lysis) of a HIV-1 specific CTL clone (effector) using a HIV-1-peptide-loaded B cell line labeled with [51Cr] as
a target with or without expanded Tregs at a 1 Effector:1 Treg :1 Target ratio. D. Example of gating strategy used to isolate Tregs from the peripheral
blood of an HIV-1-infected infant (Left). Numbers of cells counted during the expansion of these Tregs (Middle). Percentage of suppression of the
expanded Tregs or expanded Tconvs on activated CD4+ T cells when co-cultured with autologous CFSE loaded PBMC at a 1:1 ratio (Right). E. Example
of gating strategy used to isolate Tregs from the colon of an HIV-1-infected individual (Left). The middle panel represents the numbers of cells
counted during the expansion of these Tregs (Middle). Percentage of suppression of the expanded Tregs (n = 1 HIV-1-negative sample +4 HIV-1-
positive samples) or expanded Tconvs (n = 1 HIV-1-negative sample +4 HIV-1-positive samples) isolated from the GALT on activated CD8+ T cells when
co-cultured with CFSE loaded PBMC at a 1:1 ratio (Right).
doi:10.1371/journal.pone.0086920.g004
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HIV-1-specific CTL clone after 4 h of co-culture at a ratio of 1:1:1
CTL/Treg/BCL target.
We here demonstrate that Tregs expanded from HIV-1-positive
individuals retain their suppressive function in vitro, as shown by
their capacity to suppress the proliferation of activated T cells and
the cytolytic activity of HIV-1-specific CTL clones.
Expansion of Tregs from HIV-1-infected infant and gut-
associated lymphoid tissue (GALT)
One of the major limitations in studying Treg biology in the
context of HIV-1 infection is the limited amount of Tregs present
in small volume samples. We therefore next investigated if
functional Tregs can be expanded from tissue and small volume
samples. Figures 4D and E show examples of Tregs isolated from
the peripheral blood of an HIV-1-infected infant and from the
colon of an HIV-1-infected adult. Using a flow-cytometry cell
sorter we isolated 186103 and 3.56103 viable Tregs from 156106
frozen PBMC and 1106106 cells isolated from fresh colonic tissue,
respectively (gating is shown on Figure 4D and E, left). After 7
days, the cell number reached 2.96106 (i.e. 161 fold-change) for
the Tregs isolated from the infant specimen, whereas it reached
2.46105 (i.e. 69 fold-change) after 9 days of culture of Tregs
isolated from the adult GALT (Figure 4D and E, middle).
Suppressive function was quantified by flow-cytometry prolif-
eration assays (Figure 4D and E, right) and showed that Tregs
isolated from the peripheral blood of HIV-1-infected infants and
the GALT of HIV-1-infected adults were functional and highly
suppressive. In total Tregs from 5 gut samples (1 from a HIV-1-
negative and 4 from HIV-1-positive individuals) were expanded
and yielded similar results.
Discussion
Many unanswered questions related to Tregs in the context of
HIV-1 immunopathogenesis remain and it is yet incompletely
understood if this cell population contributes to promotion or
prevention of disease progression. Studying Tregs in CD4+ T cell-
depleted individuals has proven to be difficult in the context of
limiting cell numbers and it is unknown to date, if Tregs can be
expanded from HIV-1-positive individuals for experimental or
potential future therapeutic use.
In the present study we describe for the first time the successful
in vitro expansion of CD4+ regulatory T cells from HIV-1 positive
individuals. Expanded Tregs from HIV-1-infected donors dis-
played the phenotype and function of genuine regulatory T cells
with a preserved TCR repertoire. Expansion of functional Tregs
isolated from different blood and tissue compartments of HIV-1
patients with preserved suppressive capacity suggests that these
cells are not intrinsically defective in the context of HIV-1
infection. Indeed, when comparing the expanded Tregs isolated
from HIV-positive individuals (HIV controllers and individuals
with chronic HIV-1 infection) and healthy control subjects, no
differences in their capacity to inhibit proliferation of activated
lymphocytes were observed after in vitro expansion. These results
support our previous studies demonstrating conserved suppressive
function between Tregs isolated ex vivo from HIV-1 positive and
negative individuals [13]. However, like these previously reported
ex vivo functional data, our results do not exclude the possibility of
impairment of in vivo Treg function during HIV infection, e.g. in a
pathologically impaired tissue microenvironment, through dysreg-
ulated interplay with antigen presenting cells such as dendritic cells
[43] or loss of function as a result of direct HIV-1 infection
[unpublished data], [44]. Our data also suggest that expansion of
functional Tregs from HIV-infected individuals theoretically raises
the possibility to use these cells therapeutically, should an
appropriate clinical indication outside of their HIV disease
(transplantation, autoimmune disease) arise. However, immuno-
therapy targeting Tregs in the context of HIV-1 infection remains
controversial [45,46] and will require further careful investigation
into the role of Tregs in HIV disease.
The concept of immune silencing and potentially enhancing
Treg function in vivo to control HIV-1-related immune activation
and virus replication in conventional T cells is appealing, yet
challenging to achieve. IL-2 cytokine therapy in humans promotes
the generation and proliferation of effector T cells and has been
shown to improve CD4 counts in HIV-1-positive individuals but
not their clinical outcomes [47]. Interestingly, IL-2 treatment of
HIV-1-infected patients on suppressive antiretroviral therapy
resulted in the expansion of Tregs, which may have impaired
the function of conventional CD4+ T cells [48] and could explain
the overall disappointing results of this approach. Indeed, the
suppressive capacity of Tregs critically depends on IL-2 [49]. In a
SIV animal model, IL-2 treatment resulted again in Treg
expansion but also promoted CD4+ T cell activation and
spontaneous apoptosis [50], further highlighting the difficulties of
using IL-2 in vivo to modulate the course of HIV-1 infection.
One alternative, but still highly experimental approach of
enhancing Treg activity in vivo would be the transfer of autologous
Tregs. In the transplantation setting, numerous animal studies
described the use of polyclonally expanded autologous Tregs to
induce allograft control [51,52,53,54] and control autoimmune
diseases [55,56,57]. Indeed adoptive transfer of activated Tregs
provided neuroprotection in an HIV-1 encephalitis mouse model
[58] and this was linked to down-regulation of proinflammatory
cytokines, oxidative stress, and viral replication. However, besides
technical difficulties, a major risk and challenge of isolating and
expanding Tregs from HIV-1 infected donors for potential cell
therapy is the re-activation of replicating virus, which needs
additional careful exploration, but could potentially be managed
safely in the era of HAART. Future studies should aim to reach
the highest degree of Treg purity (e.g. using rapamycin alone [19]
or in combination with retinoic acid [43]) and stability possible
(e.g. using Oligodeoxynucleotides [39]) as adoptive transfer of
activated conventional CD4+ T cells in the context of HIV-1 may
add ‘‘fuel to the fire’’ in the form of new targets for the virus.
The Treg expansion approach may also be used to enrich or
detect small Treg subsets such as antigen-specific Tregs [59].
Moreover, expanding functional Tregs from different tissue
compartments could prove to be a useful tool to study the biology
and impact of Tregs on HIV-1 infection, as the Treg TCR
repertoire varies by anatomic location, presumably due to antigen
encounter [60]. Tregs are important for maintenance of intestinal
immune homeostasis by controlling inflammatory responses
triggered by continuous antigen challenge in healthy individuals
[61]. During the earliest days of HIV-1 infection, increased
inflammation and immune activation occur in the gut associated
lymphoid tissue [62], however little is known about the role and
specificity of Tregs present in GALT and other mucosal tissues
during early HIV-1 events [63,64]. Difficult access to mucosal
samples and the scarcity of the Treg population, which contribute
to the lack of data, are drawbacks that could be partially overcome
by Treg expansion approaches such as outlined here.
We therefore believe that this study will greatly facilitate the
investigation of the role of Tregs during HIV-1 infection. A more
detailed understanding of this unique T cell subset and its
influence on HIV pathogenesis, immune activation and HIV-1-
specific immunity will be critical for the design of potential
immunotherapeutic strategies targeting Tregs (both up regulation
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and down regulation of Treg activity are under active investigation
and consideration) [46] and possibly in the context of HIV-1
eradication [65].
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